Biopharma Stocks Transformative Innovation for the Future of Health

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) just announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date. Mino-Lok: Citius recently announced positive topline data from the Phase 3 study of Mino-Lok® in catheterrelated bloodstream infections (CRBSIs). Primary and secondary endpoints were met with statistical significance. In addition to the initial indication, two investigator-initiated Phase 1 studies of LYMPHIR are underway to explore how the differenti ...